Journal Article Epublish
PubMed: 40201313 DOI: 10.20517/cdr.2024.195
Circular RNAs modulate cancer drug resistance: advances and challenges.
Cancer Drug Resist 8:17
Authors: Jinghan Hua, Zhe Wang, Xiaoxun Cheng, Jiaojiao Dai, Ping Zhao
Affiliations
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China. Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230000, Anhui, China.
- Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230000, Anhui, China.
- Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230000, Anhui, China. The Second Clinical School of Anhui Medical University, Hefei 230000, Anhui, China.
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China.
Abstract
Acquired drug resistance is a main factor contributing to cancer therapy failure and high cancer mortality, highlighting the necessity to develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with a closed loop structure, possess characteristics including high stability, which provide unique advantages in clinical application. Growing evidence indicates that aberrantly expressed circRNAs are associated with resistance against various cancer treatments, including targeted therapy, chemotherapy, radiotherapy, and immunotherapy. Therefore, targeting these aberrant circRNAs may offer a strategy to improve the efficiency of cancer therapy. Herein, we present a summary of the most recently studied circRNAs and their regulatory roles on cancer drug resistance. With the advances in artificial intelligence (AI)-based bioinformatics algorithms, circRNAs could emerge as promising biomarkers and intervention targets in cancer therapy.
MeSH
Drug Resistance, Neoplasm, Pharmaceutical Preparations, Neoplasms, Rna, Circular, Biomarkers, Therapeutics, Artificial Intelligence, Drug Resistance